KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Five-Year Survival After Perioperative Nutritional Supplementation in Gastrointestinal Cancer Surgery: Follow-Up of the PROGRESS Feasibility Trial.

Najda P Tejani, Lily Park, Mya Pierini, Jeffrey Ai, Leyo Ruo, Marko Simunovic, Pablo E Serrano

J Surg Res 328 835-844

PMID43050999
PMCID-
DOI10.1016/j.jss.2026.10.034
发表日期2026-11-18
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

INTRODUCTION: Malnutrition and metabolic dysregulation are common among patients undergoing gastrointestinal cancer surgery and are associated with adverse postoperative outcomes. While perioperative nutritional supplementation has been associated with improved early postoperative recovery, its association with long-term oncologic survival remains unclear. METHODS: This is a secondary survival analysis of PROGRESS, a single-center, double-blinded, placebo-controlled feasibility randomized controlled trial conducted between 2018 and 2020 in Ontario, Canada. Adults undergoing elective resection for gastrointestinal malignancies were randomized 1:1 to perioperative nutritional supplementation (protein, immuno-nutrition, and carbohydrate-loading solutions) or placebo. Progression-free survival (PFS) and overall survival (OS) were assessed up to 60 mo using Kaplan-Meier methods and Cox proportional hazards regression. RESULTS: Of 71 enrolled patients, 56 were included in the final analysis (30 placebo, 26 intervention). Recurrence occurred in 36.7% of the placebo group and 57.7% of the intervention group (P = 0.116); mortality occurred in 46.7% and 46.2%, respectively (P = 0.969). Five-year PFS was 46.7% (placebo) versus 42.3% (intervention), and 5-y OS was 53.3% versus 53.8%, with no statistically significant differences. Notably, the intervention group had a more favorable tumor distribution (fewer pancreatic cancers, more colorectal cancers), yet no survival advantage was observed. Perioperative red blood cell transfusion was independently associated with worse PFS (hazard ratio 5.35, 95% confidence interval 2.30-12.44) and OS (hazard ratio 7.83, 95% confidence interval 3.13-19.58); tumor location and the number of positive lymph nodes were also associated with OS. CONCLUSIONS: Perioperative nutritional supplementation was not associated with improved long-term survival in this heterogeneous gastrointestinal cancer cohort, consistent with recent evidence suggesting limited additional benefit of immune-enhanced formulations over standard nutritional support. However, this study demonstrates the feasibility of incorporating long-term survival end points into perioperative nutrition trials and underscores the importance of adequate stratification by tumor type and procedure type in future definitive studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。